DrugMoaMiner: A computational tool for mechanism of action discovery and personalized drug sensitivity prediction
- 1 February 2016
- conference paper
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- p. 368-371
Abstract
Heterogeneity of genomic instabilities among individual patients is believed to be a major cause of drug response heterogeneity. Cancer patients who are sensitive to anti-cancer drugs are often re-examined to understand the unknown mechanism of action (MoA) of given drugs. For example, a non-small cell lung cancer (NSCLC) patient was reported to be responsive to Dasatinib treatment and remained cancer-free four years later. Though follow-up genomic analysis showed the patient bears an inactivating BRAF [1]mutation in the tumor, the MoA remains unclear. There are two challenges in uncovering the MoA. First, Dasatinib is a kinase inhibitor, which often has many protein targets. Second, the downstream MoA signaling pathways regulated by these targets are too complicated to delineate. Currently, there is no computational tool that can effectively address both challenges. To fill this gap, we developed a computational tool DrugMoaMiner (Drug MoA Miner) that can be used to identify the comprehensive set of kinase inhibitor targets; delineate the underlying drug MoA; and predict personalized sensitivity to a given drug based on an individual's gene expression profiles. We applied the DrugMoaMiner to lung cancer cell lines to uncover the potential MoA signaling network of Dasatinib sensitivity; our result is in agreement with previous protein data analysis. Moreover, we can predict Dasatinib response of an independent set of NSCLC cell lines using the MoA signaling network uncovered.Keywords
This publication has 20 references indexed in Scilit:
- Kinase-Impaired BRAF Mutations in Lung Cancer Confer Sensitivity to DasatinibScience Translational Medicine, 2012
- Comprehensive analysis of kinase inhibitor selectivityNature Biotechnology, 2011
- ChEMBL: a large-scale bioactivity database for drug discoveryNucleic Acids Research, 2011
- Finding undetected protein associations in cell signaling by belief propagationProceedings of the National Academy of Sciences, 2010
- The power of protein interaction networks for associating genes with diseasesBioinformatics, 2010
- Human Protein Reference Database--2009 updateNucleic Acids Research, 2008
- Reactome knowledgebase of human biological pathways and processesNucleic Acids Research, 2008
- A quantitative analysis of kinase inhibitor selectivityNature Biotechnology, 2008
- KEGG for linking genomes to life and the environmentNucleic Acids Research, 2007
- Network‐based classification of breast cancer metastasisMolecular Systems Biology, 2007